Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer

Journal of Chemotherapy

Volumn 23, Issue 2, 2011, Pages 110-113

  di Seri, M ^a   de Sanctis, R ^a   Quadrini, S ^a   Adua, D ^a   Stumbo, L ^a   del Signore, E ^a   Gori, B ^a   Grassi, P ^a   Basile, M L ^a   Longo, F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Capecitabine; Metastatic breast cancer; Oral chemotherapy; Oral vinorelbine

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; ERYTHROPOIETIN; HEMOPOIETIC GROWTH FACTOR; NAVELBINE; SEROTONIN ANTAGONIST; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 80052778712     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.2.110     Document Type: Article

References (11)

1. Freyer G, Delozier T, Lichinister M et al. Phase II study of oral vi norelbine in I line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21: 35-40.
2. Trillet-Lenoir V, Sommer H, Delozier T et al. Oral vinorelbine in metastatic breast cancer: long-term results of 2 phase II studies. Eur J Can cer 2004; 2(3): abstr 279.
3. Orphanos G, Alexopoulos A, Malliou S, Ioannidis G, Ardavanis A, Kandylis C, et al. A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. J Cancer Res Clin Oncol, 2009 Aug 12. [Epub ahead of print]
4. Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, et al. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol, 2010 Mar; 65(4):755-63. Epub 2009 Aug 9.
5. Finek J, Holubec L Jr, Svoboda T, Sefrhansova L, Pavlikova I, Votavova M, et al. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res, 2009 Feb;29(2):667-70.
6. Estevez LG, Batista N, Sanchez-Rovira P, Velasco A, Provencio M, Leon A, et al. A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer, 2008 Apr;8(2): 149-54.
7. Nole F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, et al. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol, 2009 Sep; 64(4):673-80. Epub 2009 Jan 31.
8. Chan A, Verrill M. Capecitabine and vinorelbine in metastatic breast cancer. Eur J Cancer, 2009 Sep; 45(13):2253-65. Epub 2009 May 20.
9. Bonneterre J, Penel N. Vinorelbine in breast cancer. Expert Opin Phar-macother, 2008 Nov;9(16):2901-10.
10. Overmoyer B. Options for the treatment of patients with taxane-re-fractory metastatic breast cancer. Clin Breast Cancer, 2008 Mar; 8, Suppl 2:S61-S70.
11. Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guide-lines for diagnosis, treatment and follow-up. Annals of Oncology 2010; 21, Suppl 5: vl5-vl9.